Kissei Pharmaceutical KSPHF Stock
Kissei Pharmaceutical Price Chart
Kissei Pharmaceutical KSPHF Financial and Trading Overview
| Kissei Pharmaceutical stock price | 25.77 USD |
| Previous Close | 25.77 USD |
| Open | 30.28 USD |
| Bid | 22.96 USD x 10000 |
| Ask | 26.64 USD x 10000 |
| Day's Range | 30.28 - 30.28 USD |
| 52 Week Range | 25.1 - 31.9 USD |
| Volume | 100 USD |
| Avg. Volume | 0 USD |
| Market Cap | 1.07B USD |
| Beta (5Y Monthly) | -0.162 |
| PE Ratio (TTM) | 12.449276 |
| EPS (TTM) | 2.07 USD |
| Forward Dividend & Yield | 0.83 (3.21%) |
| Ex-Dividend Date | September 29, 2026 |
| 1y Target Est | N/A |
KSPHF Valuation Measures
| Enterprise Value | -49223782400 USD |
| Trailing P/E | 12.449276 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.0108334 |
| Price/Book (mrq) | 0.7356514 |
| Enterprise Value/Revenue | -0.499 |
| Enterprise Value/EBITDA | -69.11 |
Trading Information
Kissei Pharmaceutical Stock Price History
| Beta (5Y Monthly) | -0.162 |
| 52-Week Change | -14.89% |
| S&P500 52-Week Change | 21.71% |
| 52 Week High | 31.9 USD |
| 52 Week Low | 25.1 USD |
| 50-Day Moving Average | 25.77 USD |
| 200-Day Moving Average | 26.37 USD |
KSPHF Share Statistics
| Avg. Volume (3 month) | 0 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 41.45M |
| Float | 34.76M |
| Short Ratio | N/A |
| % Held by Insiders | 22.87% |
| % Held by Institutions | 23.93% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 120 |
| Trailing Annual Dividend Yield | 465.65% |
| 5 Year Average Dividend Yield | 164.00% |
| Payout Ratio | 0.36189997 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | March 31, 2027 |
Profitability
| Profit Margin | 14.18% |
| Operating Margin (ttm) | 4.68% |
| Gross Margin | 46.82% |
| EBITDA Margin | 0.72% |
Management Effectiveness
| Return on Assets (ttm) | -0.95% |
| Return on Equity (ttm) | 6.47% |
Income Statement
| Revenue (ttm) | 98.6B USD |
| Revenue Per Share (ttm) | 2378.74 USD |
| Quarterly Revenue Growth (yoy) | 5.40% |
| Gross Profit (ttm) | 46.17B USD |
| EBITDA | 712.25M USD |
| Net Income Avi to Common (ttm) | 13.98B USD |
| Diluted EPS (ttm) | 2.07 |
| Quarterly Earnings Growth (yoy) | 4.50% |
Balance Sheet
| Total Cash (mrq) | 52.95B USD |
| Total Cash Per Share (mrq) | 1277.48 USD |
| Total Debt (mrq) | 1.25B USD |
| Total Debt/Equity (mrq) | 0.54 USD |
| Current Ratio (mrq) | 6.026 |
| Book Value Per Share (mrq) | 35.03018 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Kissei Pharmaceutical
| Country | United States |
| State | N/A |
| City | Matsumoto |
| Address | 19-48, Yoshino |
| ZIP | 399-8710 |
| Phone | 81 2 6325 9081 |
| Website | https://www.kissei.co.jp |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 1786 |
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, that is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0914 that is in Phase I clinical trial to treat Graves' disease; KPS-0373, that is in Phase III clinical trial to treat Spinocerebellar degeneration; KSP- 0576 that is in Phase I clinical trial to treat interstitial cystitis and bladder pain syndrome; and KSP-0930, which is in Phase I clinical trial to treat Narcolepsy. It also develops Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply food; purchases and sells related materials; and offers system development and information processing, facility and equipment management, and information gathering and development support services. Further, it engages in information equipment rentals; insurance agency business; manufactures and sells noodles; construction contracting; and computer system design and development, and cloud services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is based in Matsumoto, Japan.
Q&A For Kissei Pharmaceutical Stock
What is a current KSPHF stock price?
Kissei Pharmaceutical KSPHF stock price today per share is 25.77 USD.
How to purchase Kissei Pharmaceutical stock?
You can buy KSPHF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kissei Pharmaceutical?
The stock symbol or ticker of Kissei Pharmaceutical is KSPHF.
Which industry does the Kissei Pharmaceutical company belong to?
The Kissei Pharmaceutical industry is Drug Manufacturers - Specialty & Generic.
How many shares does Kissei Pharmaceutical have in circulation?
The max supply of Kissei Pharmaceutical shares is 41.45M.
What is Kissei Pharmaceutical Price to Earnings Ratio (PE Ratio)?
Kissei Pharmaceutical PE Ratio is 12.44927600 now.
What was Kissei Pharmaceutical earnings per share over the trailing 12 months (TTM)?
Kissei Pharmaceutical EPS is 2.07 USD over the trailing 12 months.
Which sector does the Kissei Pharmaceutical company belong to?
The Kissei Pharmaceutical sector is Healthcare.
